IL-6 trans-signaling: the heat is on.
暂无分享,去创建一个
[1] H. Ito. Anti-interleukin-6 therapy for Crohn's disease. , 2003, Current pharmaceutical design.
[2] S. Rose-John,et al. Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.
[3] M. Neurath,et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.
[4] C. Ding,et al. Technology evaluation: MRA, Chugai. , 2003, Current opinion in molecular therapeutics.
[5] T. Kishimoto,et al. Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.
[6] M. Neurath,et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.
[7] T. S. Wilkinson,et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.
[8] P. Wallace,et al. Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. , 2004, Immunity.
[9] S. Rose-John,et al. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. , 2002, Biochimica et biophysica acta.